Cullinan Therapeutics (CGEM) Total Liabilities (2020 - 2023)
Historic Total Liabilities for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $25.9 million.
- Cullinan Therapeutics' Total Liabilities fell 1677.65% to $25.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $25.9 million, marking a year-over-year decrease of 1677.65%. This contributed to the annual value of $26.1 million for FY2022, which is 12087.88% up from last year.
- As of Q3 2023, Cullinan Therapeutics' Total Liabilities stood at $25.9 million, which was down 1677.65% from $22.4 million recorded in Q2 2023.
- In the past 5 years, Cullinan Therapeutics' Total Liabilities ranged from a high of $62.6 million in Q2 2022 and a low of $5.8 million during Q2 2021
- Its 4-year average for Total Liabilities is $22.1 million, with a median of $20.2 million in 2022.
- Its Total Liabilities has fluctuated over the past 5 years, first surged by 97742.99% in 2022, then plummeted by 6421.9% in 2023.
- Cullinan Therapeutics' Total Liabilities (Quarter) stood at $14.4 million in 2020, then decreased by 17.94% to $11.8 million in 2021, then surged by 120.88% to $26.1 million in 2022, then decreased by 0.76% to $25.9 million in 2023.
- Its last three reported values are $25.9 million in Q3 2023, $22.4 million for Q2 2023, and $29.3 million during Q1 2023.